Logo

Novo Nordisk Reports Results of Semaglutide from P-IIIa STEP 1 Trial in Patients with Obesity

Share this

Novo Nordisk Reports Results of Semaglutide from P-IIIa STEP 1 Trial in Patients with Obesity

Shots:

  • The company reported the results from the P-IIIa STEP 1 trial of the STEP programme assessing semaglutide (2.4 mg- SC- qw) vs PBO in adults with obesity for 68 wks. The results will be presented at ECO 2021
  • Results: The therapy showed 14.9% weight loss- 43.8% improvement in total weight-related QoL scores- 51.2% vs 32.9% participants improved weight-related physical function- 40% vs 27% participants achieved improvement in health-related physical functioning score- improved psychological well being
  • Semaglutide is an analogue of the human GLP-1 hormone- currently under investigation for chronic weight management and is under FDA and EMA’s review

  Ref: PRNewswire | Image: Novo Nordisk

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions